top of page

September 26, 2025

Amgen

Juncos-PR

Expansion to support increased drug production and integrate innovative advanced technologies at the company's biologics manufacturing facility in Juncos.

Disease Area:

Drug Type:

May 4, 2026

Amgen

Juncos-PR

Additional investment at the company’s Juncos biologics manufacturing facility. 


Combined with a $650 million investment in September 2025, this additional investment brings the company’s total commitment to this facility to $950 million.

Disease Area:

Drug Type:

May 6, 2026

Eli Lilly

Lebanon-IN

Investment across two of the company’s three sites in Lebanon, Indiana.


The investment will incorporate new process designs and technologies at one of the company's future active pharmaceutical ingredient sites as well as at its first dedicated genetic medicine manufacturing facility.


Part of a larger, previously announced $23 billion company investment.

Disease Area:

Drug Type:

April 30, 2026

Novartis

Morrisville-NC

Finalized plans to build a manufacturing facility focused on active pharmaceutical ingredients(API) for solid dosage tablets, capsules and RNA therapeutics. The 56,200-square-foot site will expand the company’s presence in North Carolina to five facilities.


Plans were initially announced in November 2025.


Part of a larger, previously announced $23 billion company investment.

Disease Area:

Drug Type:

April 22, 2026

AbbVie

Durham-NC

A 185-acre campus that will integrate advanced manufacturing and laboratory technologies with AI to support the production of the company’s immunology, neuroscience and oncology medicines.


The project will create about 734 jobs in engineering, manufacturing operations and other technical roles and will generate more than 2,000 construction jobs during campus development.


Part of a larger, previously announced $100 billion company investment.

Disease Area:

Drug Type:

March 9, 2026

CSL

Kankakee-IL

An expansion of a manufacturing facility that will increase production of life-sustaining, plasma-derived therapies for people living with rare and serious diseases and other acute medical issues. The development will add at least 300 jobs.


Added details made public for an original November 2025 announcement.

Disease Area:

Drug Type:

February 25, 2026

Novartis

Denton-TX

A new 46,000-square-foot radioligand therapy (RLT) manufacturing site, the company’s fifth in the US and first manufacturing facility in Texas.


Part of a larger, previously announced $23 billion company investment.

Disease Area:

Drug Type:

February 23, 2026

AbbVie

North Chicago-IL

Two new active pharmaceutical ingredient (API) manufacturing facilities that will integrate advanced manufacturing technologies with artificial intelligence to support the production of next-generation neuroscience and obesity medications. To support these new facilities, AbbVie will hire 300 people in North Chicago, including engineers, scientists, manufacturing operators and lab technicians.


Part of a larger, previously announced $100 billion company investment.

Disease Area:

Drug Type:

No entries found matching your criteria. Please modify your filters.

bottom of page